Odyssey Health, Inc.

For the period ended Jan 31, 2025. Filed Mar 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jan 31, 2025 · Filed Mar 14, 2025

ODYYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	Three Months Ended January 31,		Six Months Ended January 31,
	2025	2024	2025	2024
Research and development expense	$–	$42,765	$–	$65,766
Stock-based compensation	36,131	67,391	96,618	1,000,188
General and administrative expense	120,462	437,274	639,402	938,716
Loss from operations	(156,593)	(1,157,430)	(736,020)	(2,004,670)
Gain on sale of asset	–	15,900,687	–	16,400,687
Investment revaluation	–	(1,332,980)	(370,698)	(1,332,980)
Interest expense	(63,431)	(141,601)	(132,217)	(332,462)
Other income (expense), net	(102)	8,890	(97)	8,956
Net income (loss)	(220,126)	13,277,566	(1,239,032)	12,739,531
Deemed dividend	–	(63,455)	–	(63,455)
Net income (loss) attributable to common shareholders	$(220,126)	$13,214,111	$(1,239,032)	$12,676,076
Basic net income (loss) per share	$(0.00)	$0.14	$(0.01)	$0.14
Diluted net income (loss) per share	$(0.00)	$0.12	$(0.01)	$0.12
Shares used for basic net income (loss) per share	104,709,763	91,975,356	104,709,763	89,879,237
Shares used for diluted net income (loss) per share	104,709,763	114,056,382	104,709,763	112,043,228

*The accompanying notes are an integral part of these condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.